DS
AVBP icon

David Shaw’s ArriVent BioPharma AVBP Stock Holding History

David Shaw’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.3M Buy
872,011
+503,216
+136% +$14.9M 0.01% 1039
2026
Q1 		$8.51M Buy
368,795
+135,471
+58% +$3.06M 0.01% 1773
2025
Q4 		$4.69M Buy
+233,324
New +$4.86M ﹤0.01% 2359
2024
Q4 		– Sell
-8,775
Closed -$206K – 4963
2024
Q3 		$206K Buy
+8,775
New +$199K ﹤0.01% 4143

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's AVBP Position: Q2 2026 in Review

David Shaw increased its ArriVent BioPharma (AVBP) stake by 136% in Q2 2026, buying an estimated $14.9M and bringing the position to 872,011 shares worth $30.3M. The position accounts for 0.01% of the portfolio, ranked #1039.

David Shaw first reported a position in AVBP in Q3 2024 and has held it in 4 quarters since. 156 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • David Shaw held 872,011 shares of ArriVent BioPharma worth $30.3M as of Q2 2026.
  • David Shaw bought 503,216 ArriVent BioPharma shares in Q2 2026, an estimated $14.9M.
  • ArriVent BioPharma made up 0.01% of David Shaw's portfolio in Q2 2026, its #1039 holding.
  • David Shaw first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 4 quarters since.
  • 156 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.